Shanghai Pulmonary Hospital, Shanghai, China: Carcinoma, Non-Small-Cell Lung trials

The registry lists 47 Carcinoma, Non-Small-Cell Lung studies with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor. 33 are open to participants now and 0 have results posted.

Phase 2 28Phase 3 5Phase 4 2No phase 13(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLCRecruitingNCT07754812Phase 4
• Neoadjuvant SF-SBRT Plus Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC.Not yet recruitingNCT07608159Phase 3
• Oral Paclitaxel as Neoadjuvant Therapy in Elderly NSCLC: A Phase II TrialNot yet recruitingNCT07599163Not applicable
• Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II TrialNot yet recruitingNCT07517640Phase 2
• Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer PatientsNot yet recruitingNCT07493980Phase 2
• A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based RegimensNot yet recruitingNCT07469488Phase 4
• Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung CancerRecruitingNCT07410975Phase 2
• IBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung CancerRecruitingNCT07408635Phase 2
• Patient-derived Tumor-like Cell Cluster Model-based Precision Treatment Strategy on Non-small Cell Lung CancerRecruitingNCT07328945
• Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung CancerRecruitingNCT07323056Phase 2
• Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLCNot yet recruitingNCT07235306Phase 2
• Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer PatientsRecruitingNCT06987734Phase 2
• Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical StudyNot yet recruitingNCT06946836Phase 2
• Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLCNot yet recruitingNCT06837948Phase 2
• The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk FactorsNot yet recruitingNCT06772610Phase 2
• Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)Not yet recruitingNCT06644313Phase 2
• Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingNCT06620822Phase 2
• Induction Therapy With Serplulimab Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung CancerNot yet recruitingNCT06591910
• Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaRecruitingNCT06528847Phase 2
• The Clinical Characteristics and Efficacy of Immunotherapy in First-line PD-L1-negative Advanced NSCLC PatientsNot yet recruitingNCT06496009
• SHR-A1921 Combined With Adebrelimab in the Treatment of Advanced NSCLC Who Failed the Previous Standard First-line TreatmentNot yet recruitingNCT06480136Phase 2
• LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingNCT06479759Phase 2
• Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingNCT06463171Phase 2
• Neoadjuvant Therapy With Iruplinalkib for Potentially Resectable ALK Positive NSCLC: A Single Arm, Exploratory TrialNot yet recruitingNCT06282536Phase 2
• Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT06109402Phase 2
• Exploration on the Value of MRD Based on ctDNA Detection in Predicting Recurrence of Resected Non-small Cell Lung CancerRecruitingNCT05965024
• Deep Learning Signature for Predicting Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in Non-small Cell Lung CancerRecruitingNCT05925751
• Deep Learning Signature for Predicting Aggressive Histological Pattern in Resected Non-small Cell Lung CancerRecruitingNCT05925738
• Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialNot yet recruitingNCT05891080Phase 2
• Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung CancerRecruitingNCT05766800Phase 2
• Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)Not yet recruitingNCT04772287Phase 3
• Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II StudyRecruitingNCT04762030Phase 2
• Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung CancerRecruitingNCT04728724Phase 2
• Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.Active, not recruitingNCT07274761Phase 2
• A Retrospective Cohort Analysis of SMARCA4-Deficient Lung CancerCompletedNCT07121387
• CX3CR1+T Cell Predict Immunotherapy EfficacyCompletedNCT06054152
• Deep Learning Signature for Predicting Occult Nodal Metastasis of Clinical N0 Lung CancerStatus unknownNCT05425134
• Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung CancerCompletedNCT04702009Phase 2/3
• Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung CancerActive, not recruitingNCT04685070Phase 2
• Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung CancerTerminatedNCT04422392Phase 2
• Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04379739Phase 2
• Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 InhibitorsStatus unknownNCT04355806
• Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene MutationStatus unknownNCT04137718
• NGS Combined With RNAseq on Tumor Immune Escape in NSCLCStatus unknownNCT03764917
• Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung CancerCompletedNCT03331588Phase 3
• EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT03002844Phase 2
• EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion PolymorphismStatus unknownNCT02859077Phase 3